TOP > 外国特許検索 > COMPOSITION FOR PREVENTING OR AMELIORATING LOSS OF HAIR AND GRAYING OF HAIR, AND USE THEREOF

COMPOSITION FOR PREVENTING OR AMELIORATING LOSS OF HAIR AND GRAYING OF HAIR, AND USE THEREOF

外国特許コード F170009143
整理番号 (S2016-0313-N0)
掲載日 2017年8月8日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP000610
国際公開番号 WO 2017122668
国際出願日 平成29年1月11日(2017.1.11)
国際公開日 平成29年7月20日(2017.7.20)
優先権データ
  • 特願2016-003424 (2016.1.12) JP
発明の名称 (英語) COMPOSITION FOR PREVENTING OR AMELIORATING LOSS OF HAIR AND GRAYING OF HAIR, AND USE THEREOF
発明の概要(英語) The present invention provides a composition for preventing or ameliorating newly occurring loss of hair and a composition for preventing or ameliorating graying of hair. More specifically, the present invention provides a composition containing, as an active ingredient, an agent for stabilizing the expression of collagen XVII, preferably a collagen XVII decomposition inhibitor such as an ELANE inhibitor, or an agent for promoting the repairing of DNA or an agent for inhibiting the damage of DNA. When a composition containing, as an active ingredient, a collagen XVII decomposition inhibitor, such as an ELANE inhibitor, is administered to a mammal, an advantageous effect for preventing the loss of hair and the graying of hair can be produced. As the ELANE inhibitor, the collagen XVII decomposition inhibitor or the agent for promoting the repairing of DNA, a low-molecular-weight compound, a polypeptide, a protein, an antibody, or a nucleic acid drug such as an antisense oligonucleotide and siRNA can be used. Also provided is a method for screening for a substance that is effective for the prevention of the loss of hair and the graying of hair.
従来技術、競合技術の概要(英語) BACKGROUND ART
Tissue and organ with age, a decline in the function and structure as can be seen. Tissue and individual level in order to understand the aging, so far many hypotheses have been proposed. Or an individual with the expression of aging genes involved in the life of the device has been known as, at the tissue level actually change how the animal age in the field, the actual in vivo sufficiently that the mechanism is not clear.
DNA replication error, active oxygen, telomere end problem, can occur due to chromosomal abnormalities such as endogenous DNA damage, which accumulate in cells that constitute the tissue is known, this being related to tissue aging. Gray hair such as hair loss or trait may be a typical aging, premature aging syndrome seen as well as the endogenous genome instability, due to environmental factors such as radiation exogenous genome instability is also promoted by the known.
A decline in the tissue by the heretofore genome instability, cell senescence and cell death have been described. However, the typical cells having the characteristics of the aging cells, to induce genome instability to the skin on the other hand quickly appearance but, rather skin pigment cells such as nevi or characteristically seen in papilloma, thought to be related to carcinogenesis inhibiting. Today, an age-associated changes in tissue stem cells (Stem cell aging) is, today, which is considered one of the characteristics of aging is, or the fate of tissue stem cells and aged, how DNA damage effect upon its fate or, further aging of tissues and organs most has still revealed a role in the course is not.
Hair follicle stem cells, hair follicle bulge as among localized in an area, the reproduction of hair for each cycle to be responsible for the hair (Patent Document 1; non-patent document 1). Mouse hair follicle stem cells, generally does not exhibit a clear decline but, in practice with increasing age is long and the telogen phase, hair follicle stem cell in which a change in cytokine, and decreases the colony forming ability of known. On the other hand, the mammal can be a long life span of the hair with advancing age are losing hair follicles.
Is generally the stimulation of hair growth, growth phase (anagen), catagen, rest (telogen) (non-patent document 2) classified into. In the case of human hair, then the growth period after 2-7 years, catagen, telogen phase through, the hair loss.
As the main function of the hair, trauma protection from direct sunlight, and prevention of loss of body temperature, hair follicle stem cells of the skin also has a role as a storehouse. In addition, the hair, mediate important social and communication, decrease the amount of the hair may result in the decrease of the QOL of people.
Some of the alopecia, male pattern alopecia, female-type alopecia, seborrheic alopecia, senile alopecia, alopecia areata, drug-induced hair loss, scarring alopecia, post-partum alopecia occurs after birth and the like. And drug-induced alopecia is androgenetic alopecia or scarring, such as anti-cancer treatment and each X-ray irradiation induced iatrogenic side effects of those. However, these hair loss is a measure for, at the moment it is not well-established.
The current, major pharmaceutical accepted as hair growth, hair growth agents include, minoxidil and finasteride is. Minoxidil is, initially, the main working orally vasodilation has been developed as a therapeutic agent for hypertension is medication, hypertension therapeutic agent to a patient undergoing treatment was adapted, and dilates the blood vessels, such as hirsutism is promotes the regeneration of hair was observed, the external preparation of the hair again as medical developed pharmaceutical product. Minoxidil hair papilla cells of promoting production of growth factors (such as VEGF) and vascular smooth muscle ATP sensitive K through the activation of the channel to urge the vasodilation. Thus, growth of hair follicles from the telogen phase or to its initial, extended growth of thicker hair growth effect has been known.
DHT (dihydrotestosterone) in the frontal region and the head top portion is about that act to inhibit the growth of hair. Finasteride is, DHT to testosterone (male sex hormones) is an enzyme that converts a 5 - α reductase type 2 inhibiting, act by suppressing the generation of DHT. Male sex hormones of benign prostate hyperplasia caused by a therapeutic agent for the treatment of male pattern alopecia (AGA) have been developed to apply to a pharmaceutical product.
These agents are presently commercially available but, to measures against hair loss, more effective pharmaceutical is still demanded. In the same manner, also in order to prevent white hair, an effective drug is demanded.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY
  • 発明者(英語)
  • NISHIMURA, Emi
  • MATSUMURA, Hiroyuki
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記問合せ先にご相談下さい。

PAGE TOP

close
close
close
close
close
close